TABLE 1.
Association between TMEM170B expression and clinicopathological characteristics in 38 pancreatic adenocarcinoma patients.
| Variable | All Patients (n = 38) (%) | TMEM170B expression | p Value (χ2-test) | |
|---|---|---|---|---|
| Positive (+) (n = 24) | Negative (−) (n = 14) | |||
| Gender (male/female) | 25 (65.8)/13 (34.2) | 17 (70.8)/7 (29.2) | 8 (57.1)/6 (42.9) | 0.61 |
| Age (years) (＜60/≥60) | 18 (47.4)/20 (52.6) | 11 (45.8)/13 (54.2) | 7 (50)/7 (50) | 0.8 |
| Tumor size (cm) (＜5/≥5) | 23 (60.5)/15 (39.5) | 14 (58.3)/10 (41.7) | 9 (64.3)/5 (35.7) | 0.72 |
| Tumor number (Single/Multiple) | 27 (71.1)/11 (28.9) | 18 (75)/5 (25) | 9 (64.3)/6 (35.7) | 0.40 |
| Tumor cellularity (＜61%/≥61%) | 23 (60.5)/15 (39.5) | 17 (70.8)/7 (29.2) | 6 (42.9)/8 (57.1) | 0.09 |
| Differentiation | ||||
| Well | 7 (18.4) | 5 (20.8) | 2 (14.3) | |
| Moderate | 22 (62.9) | 17 (70.8) | 5 (35.7) | 0.014* |
| Poor | 9 (23.7) | 2 (8.4) | 7 (50) | |
| pT classification | ||||
| T1–2 | 5 (13.2) | 4 (16.7) | 1 (7.1) | |
| T3 | 17 (44.7) | 12 (50) | 5 (35.7) | 0.33 |
| T4 | 16 (42.1) | 8 (33.3) | 8 (57.2) | 0.94 |
| Lymph node metastasis (Absent/Present) | 22 (62.9)/16 (37.1) | 14 (58.3)/10 (41.7) | 8 (57.2)/6 (42.8) | |
| pTNM stage I-II/III-IV | 11 (28.9)/27 (71.1) | 8 (33.3)/16 (66.7) | 3 (21.4)/11 (78.6) | 0.68 |
| CEA (＜5/≥5) | 21 (55.3)/17 (44.7) | 15 (62.5)/9 (37.5) | 6 (42.8)/8 (57.2) | 0.24 |
| CA19-9 (＜35/≥35) | 17 (44.7)/21 (55.3) | 10 (41.7)/14 (58.3) | 7 (50)/7 (50) | 0.62 |
| Cancer progression, n (%) (no/yes) | 26 (68.4)/12 (31.6) | 22 (91.7)/2 (8.3) | 4 (28.6)/10 (71.4) | <0.001 |
| Death, n (%) (no/yes) | 29 (76.3)/9 (23.7) | 23 (95.8)/1 (4.2) | 6 (42.9)/8 (57.1) | <0.001 |
NOTE: p: primary; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19–9; *: p < 0.05.